AZD9291 80 mg/40 mg
D5164C00001
Phase 3 small_molecule active
Quick answer
AZD9291 80 mg/40 mg for Stage IB-IIIA Non-small Cell Lung Carcinoma is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Stage IB-IIIA Non-small Cell Lung Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active